<p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）的股票在週一發佈的報告中被 HC Wainwright 的股票分析師重新給予了 “買入” 評級，Benzinga 報道。他們目前對該股票的目標價格為 30.00 美元。</p>
<p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些分析師也對 OLMA 發表了看法。Oppenheimer 在 3 月 19 日的研究報告中重申了 “跑贏大盤” 的評級，並將 Olema Pharmaceuticals 的目標價格下調至 25.00 美元（之前為 30.00 美元）。摩根大通將 Olema Pharmaceuticals 的目標價格從 30.00 美元下調至 28.00 美元，並在 3 月 28 日的報告中對該公司設定了 “增持” 評級。</p>
<p><strong>查看我們對 OLMA 的最新分析</strong></p>
<h2>Olema Pharmaceuticals 股票下跌 3.7%</h2>
<p>納斯達克：OLMA 週一開盤價為 4.91 美元。該公司的 50 日移動平均價格為 4.20 美元，200 日移動平均價格為 6.78 美元。Olema Pharmaceuticals 的 52 周最低價為 2.86 美元，52 周最高價為 16.62 美元。該股票的市值為 3.3552 億美元，市盈率為-2.24，貝塔值為 2.10。</p>
<p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）最近在 3 月 18 日發佈了季度財報。該公司報告每股收益（EPS）為-0.51 美元，超出分析師一致預期的-0.63 美元，超出幅度為 0.12 美元。整體來看，賣方分析師預計 Olema Pharmaceuticals 在本年度將發佈-2.33 美元的每股收益。</p>
<h2>Olema Pharmaceuticals 的機構交易</h2>
<p>機構投資者最近增加或減少了對該股票的持股。摩根大通在第三季度將其在 Olema Pharmaceuticals 的持股比例提高了 658.7%。摩根大通目前擁有 181,032 股該公司的股票，價值 2,162,000 美元，此前在上個季度增持了 157,171 股。HighTower Advisors LLC 在第四季度收購了 Olema Pharmaceuticals 的新股份，價值 510,000 美元。Hennion &amp; Walsh 資產管理公司在第四季度將其在 Olema Pharmaceuticals 的持股比例提高了 80.5%。Hennion &amp; Walsh 資產管理公司目前擁有 212,246 股該公司的股票，價值 1,237,000 美元，此前在該期間增持了 94,651 股。Alliancebernstein L.P.在第四季度將其在 Olema Pharmaceuticals 的持股比例提高了 77.7%。Alliancebernstein L.P.目前擁有 313,982 股該公司的股票，價值 1,831,000 美元，此前在上個季度增持了 137,319 股。最後，巴克萊銀行在第三季度將其在 Olema Pharmaceuticals 的持股比例提高了 105.0%。巴克萊銀行目前擁有 94,915 股該公司的股票，價值 1,133,000 美元，此前在上個季度增持了 48,614 股。機構投資者和對沖基金持有該公司 91.78% 的股票。</p>
<h2>Olema Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症的治療方法的發現、開發和商業化。其主要產品候選藥物是 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；以及 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行的一期/二期臨牀試驗，針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌，同時開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Olema Pharmaceuticals 更好</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>熊市才剛剛開始 - 這是為什麼</li>
<li>使用 MarketBeat 股息税計算器</li>
<li>這三隻 ETF 讓你在不需要金庫的情況下持有真正的黃金</li>
<li>如何投資小盤股</li>
<li>為什麼機構再次購買超微計算機股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
<p>在考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Olema Pharmaceuticals 並不在名單上。</p>
<p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OLMA

<p>HC Wainwright 重申了對 Olema Pharmaceuticals (NASDAQ:OLMA) 的 "買入" 評級，目標價為 30.00 美元。其他分析師也給出了評級，Oppenheimer 將其目標價下調至 25.00 美元，摩根大通則將其下調至 28.00 美元。Olema 的股票開盤價為 4.91 美元，市值為 3.3552 億美元。該公司報告的季度每股收益為（0.51 美元），超出預期。機構投資者持有 91.78% 的股份，顯示出機構對該公司的強烈興趣</p>

<p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report)'s stock had its &#34;buy&#34; rating reissued by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）的股票在週一發佈的報告中被 HC Wainwright 的股票分析師重新給予了 “買入” 評級，Benzinga 報道。他們目前對該股票的目標價格為 30.00 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other analysts have also weighed in on OLMA. Oppenheimer reiterated an &#34;outperform&#34; rating and issued a $25.00 target price (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase &amp; Co. reduced their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an &#34;overweight&#34; rating for the company in a report on Friday, March 28th.</p>
<div class="lb-trans"><p>其他一些分析師也對 OLMA 發表了看法。Oppenheimer 在 3 月 19 日的研究報告中重申了 “跑贏大盤” 的評級，並將 Olema Pharmaceuticals 的目標價格下調至 25.00 美元（之前為 30.00 美元）。摩根大通將 Olema Pharmaceuticals 的目標價格從 30.00 美元下調至 28.00 美元，並在 3 月 28 日的報告中對該公司設定了 “增持” 評級。</p>
</div><p><strong>Check Out Our Latest Analysis on OLMA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 OLMA 的最新分析</strong></p>
</div><h2>Olema Pharmaceuticals Stock Down 3.7 %</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票下跌 3.7%</h2>
</div><p>NASDAQ:OLMA opened at $4.91 on Monday. The company's 50 day moving average price is $4.20 and its 200-day moving average price is $6.78. Olema Pharmaceuticals has a 52 week low of $2.86 and a 52 week high of $16.62. The stock has a market cap of $335.52 million, a price-to-earnings ratio of -2.24 and a beta of 2.10.</p>
<div class="lb-trans"><p>納斯達克：OLMA 週一開盤價為 4.91 美元。該公司的 50 日移動平均價格為 4.20 美元，200 日移動平均價格為 6.78 美元。Olema Pharmaceuticals 的 52 周最低價為 2.86 美元，52 周最高價為 16.62 美元。該股票的市值為 3.3552 億美元，市盈率為-2.24，貝塔值為 2.10。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12. As a group, sell-side analysts anticipate that Olema Pharmaceuticals will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）最近在 3 月 18 日發佈了季度財報。該公司報告每股收益（EPS）為-0.51 美元，超出分析師一致預期的-0.63 美元，超出幅度為 0.12 美元。整體來看，賣方分析師預計 Olema Pharmaceuticals 在本年度將發佈-2.33 美元的每股收益。</p>
</div><h2>Institutional Trading of Olema Pharmaceuticals</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 的機構交易</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase &amp; Co. lifted its position in Olema Pharmaceuticals by 658.7% in the third quarter. JPMorgan Chase &amp; Co. now owns 181,032 shares of the company's stock valued at $2,162,000 after acquiring an additional 157,171 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at $510,000. Hennion &amp; Walsh Asset Management Inc. lifted its stake in shares of Olema Pharmaceuticals by 80.5% during the fourth quarter. Hennion &amp; Walsh Asset Management Inc. now owns 212,246 shares of the company's stock valued at $1,237,000 after buying an additional 94,651 shares during the period. Alliancebernstein L.P. increased its stake in Olema Pharmaceuticals by 77.7% in the fourth quarter. Alliancebernstein L.P. now owns 313,982 shares of the company's stock valued at $1,831,000 after purchasing an additional 137,319 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Olema Pharmaceuticals by 105.0% in the 3rd quarter. Barclays PLC now owns 94,915 shares of the company's stock valued at $1,133,000 after purchasing an additional 48,614 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該股票的持股。摩根大通在第三季度將其在 Olema Pharmaceuticals 的持股比例提高了 658.7%。摩根大通目前擁有 181,032 股該公司的股票，價值 2,162,000 美元，此前在上個季度增持了 157,171 股。HighTower Advisors LLC 在第四季度收購了 Olema Pharmaceuticals 的新股份，價值 510,000 美元。Hennion &amp; Walsh 資產管理公司在第四季度將其在 Olema Pharmaceuticals 的持股比例提高了 80.5%。Hennion &amp; Walsh 資產管理公司目前擁有 212,246 股該公司的股票，價值 1,237,000 美元，此前在該期間增持了 94,651 股。Alliancebernstein L.P.在第四季度將其在 Olema Pharmaceuticals 的持股比例提高了 77.7%。Alliancebernstein L.P.目前擁有 313,982 股該公司的股票，價值 1,831,000 美元，此前在上個季度增持了 137,319 股。最後，巴克萊銀行在第三季度將其在 Olema Pharmaceuticals 的持股比例提高了 105.0%。巴克萊銀行目前擁有 94,915 股該公司的股票，價值 1,133,000 美元，此前在上個季度增持了 48,614 股。機構投資者和對沖基金持有該公司 91.78% 的股票。</p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症的治療方法的發現、開發和商業化。其主要產品候選藥物是 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的三期臨牀試驗；以及 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行的一期/二期臨牀試驗，針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌，同時開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>The Bear Market Has Only Just Started - Here's Why</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>These 3 ETFs Let You Hold Real Gold Without the Vault</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Why Institutions Are Buying Super Micro Computer Stock Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Olema Pharmaceuticals 更好</li>
<li>最具波動性的股票，投資者需要知道的事項</li>
<li>熊市才剛剛開始 - 這是為什麼</li>
<li>使用 MarketBeat 股息税計算器</li>
<li>這三隻 ETF 讓你在不需要金庫的情況下持有真正的黃金</li>
<li>如何投資小盤股</li>
<li>為什麼機構再次購買超微計算機股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Olema Pharmaceuticals 並不在名單上。</p>
</div><p>While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 重申了對 Olema Pharmaceuticals（OLMA）的買入評級